Company news

Veru Inc. news in 2024

Veru Inc.'s news releases, calls and decks from 2024, newest first.

View company

Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

December 30, 2024

Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek

November 4, 2024

Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results

August 7, 2024

Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions

June 23, 2024

Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024

June 17, 2024

Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss

May 14, 2024

Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week

May 13, 2024

Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program

May 7, 2024

Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024

April 30, 2024

Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

April 29, 2024

Veru Announces Date of 2024 Annual Meeting of Shareholders

March 31, 2024

Veru Reschedules Annual Meeting of Shareholders

March 21, 2024

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

March 11, 2024

Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

February 26, 2024

Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss

February 19, 2024

Veru Reports Fiscal 2024 First Quarter Financial Highlights

February 7, 2024

Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs

February 5, 2024

Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024

January 24, 2024

Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss

January 7, 2024

Calls in 2024

Decks in 2024